

Abstract

A protein conjugate having a prolonged *in vivo* half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced *in vivo* stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response.